NASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Price, News & Analysis $2.14 +0.06 (+2.88%) (As of 11:41 AM ET) Add Compare Share Share Today's Range$2.01▼$2.2050-Day Range$2.06▼$6.6652-Week Range$1.57▼$8.19Volume150,965 shsAverage Volume273,924 shsMarket Capitalization$93.00 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Werewolf Therapeutics alerts: Email Address Werewolf Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside460.7% Upside$12.00 Price TargetShort InterestHealthy1.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.52) to ($1.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.66 out of 5 starsMedical Sector390th out of 879 stocksPharmaceutical Preparations Industry178th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingWerewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Werewolf Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.63% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 4.01%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOWL. Previous Next 1.8 News and Social Media Coverage News SentimentWerewolf Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for HOWL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Werewolf Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Werewolf Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Werewolf Therapeutics Stock (NASDAQ:HOWL)Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Read More HOWL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOWL Stock News HeadlinesJuly 3, 2024 | americanbankingnews.comWerewolf Therapeutics' (HOWL) Buy Rating Reaffirmed at HC WainwrightJune 28, 2024 | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by JMP SecuritiesJuly 8, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.June 25, 2024 | globenewswire.comWerewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaJune 1, 2024 | globenewswire.comWerewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsMay 30, 2024 | globenewswire.comWerewolf Therapeutics to Participate at the Jefferies Global Healthcare ConferenceMay 26, 2024 | yahoo.comHowling II: Stirba – Werewolf Bitch Streaming: Watch & Stream Online via Amazon Prime VideoMay 24, 2024 | markets.businessinsider.comBuy Rating Justified by Werewolf Therapeutics’ Advancements in WTX-124 with Promising Efficacy and Safety ProfileJuly 8, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.May 24, 2024 | markets.businessinsider.comCritical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To KnowMay 23, 2024 | globenewswire.comWerewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingMay 8, 2024 | markets.businessinsider.comWerewolf Therapeutics: Buy Rating Affirmed Amid Promising Clinical Advancements and Pipeline PotentialMay 6, 2024 | markets.businessinsider.comThe Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 ExpertsMay 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics Amid Promising Financials and Anticipated Clinical UpdatesMay 3, 2024 | investorplace.comHOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024May 3, 2024 | yahoo.comHowl: Leonardo DiCaprio Working on Live-Action Movie Told From a Dog and Wolf’s PerspectiveMay 3, 2024 | globenewswire.comWerewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | yahoo.comMy patient thinks he’s a werewolf: 10 years as an NHS psychiatristSee More Headlines Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/03/2024Today7/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOWL CUSIPN/A CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+476.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,370,000.00 Net Margins-256.33% Pretax Margin-256.33% Return on Equity-36.15% Return on Assets-23.29% Debt Debt-to-Equity Ratio0.24 Current Ratio6.71 Quick Ratio6.71 Sales & Book Value Annual Sales$19.94 million Price / Sales4.53 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book0.68Miscellaneous Outstanding Shares43,460,000Free Float34,286,000Market Cap$90.40 million OptionableOptionable Beta0.46 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Daniel J. Hicklin Ph.D. (Age 60)Founder, CEO, President, Secretary & Director Comp: $928.26kMr. Timothy W. Trost CPA (Age 66)CFO, Treasurer & Assistant Secretary Comp: $662.99kDr. Randi Isaacs M.D. (Age 68)Chief Medical Officer Comp: $702.43kDr. Chulani Karunatilake Ph.D. (Age 64)Chief Technology Officer Comp: $343.43kMs. Ellen A. Lubman M.B.A. (Age 48)Chief Business Officer Key CompetitorsAdicet BioNASDAQ:ACETPassage BioNASDAQ:PASGRain OncologyNASDAQ:RAINCurisNASDAQ:CRISXilio TherapeuticsNASDAQ:XLOView All CompetitorsInstitutional OwnershipJanus Henderson Group PLCBought 1,688,054 shares on 5/16/2024Ownership: 3.884%Vanguard Group Inc.Bought 233,909 shares on 5/10/2024Ownership: 2.554%Acadian Asset Management LLCBought 94,212 shares on 5/10/2024Ownership: 0.399%HBK Sorce Advisory LLCSold 13,227 shares on 5/9/2024Ownership: 0.031%Denali Advisors LLCBought 26,600 shares on 4/19/2024Ownership: 0.061%View All Institutional Transactions HOWL Stock Analysis - Frequently Asked Questions How have HOWL shares performed this year? Werewolf Therapeutics' stock was trading at $3.86 at the start of the year. Since then, HOWL shares have decreased by 44.6% and is now trading at $2.14. View the best growth stocks for 2024 here. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its earnings results on Friday, May, 3rd. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.04. The business earned $0.74 million during the quarter, compared to the consensus estimate of $5 million. Werewolf Therapeutics had a negative trailing twelve-month return on equity of 36.15% and a negative net margin of 256.33%. When did Werewolf Therapeutics IPO? Werewolf Therapeutics (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HOWL) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be h...Financial Markets Daily | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOWL Stock Alerts